Analysts Set GSK plc (NYSE:GSK) Price Target at $50.00

Shares of GSK plc (NYSE:GSK) have earned a consensus rating of “Buy” from the eight ratings firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $50.00.

Several research analysts have recently weighed in on GSK shares. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Berenberg Bank raised GSK to a “strong-buy” rating in a research note on Thursday, June 20th. UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Jefferies Financial Group lifted their price target on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Finally, The Goldman Sachs Group assumed coverage on GSK in a research note on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price for the company.

Institutional Investors Weigh In On GSK

Several large investors have recently added to or reduced their stakes in GSK. 1832 Asset Management L.P. increased its holdings in GSK by 9.1% during the 1st quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after purchasing an additional 257 shares during the period. Personal CFO Solutions LLC increased its stake in shares of GSK by 2.7% during the fourth quarter. Personal CFO Solutions LLC now owns 10,087 shares of the pharmaceutical company’s stock worth $374,000 after buying an additional 263 shares during the period. Boltwood Capital Management increased its stake in shares of GSK by 2.5% during the second quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after buying an additional 270 shares during the period. J.W. Cole Advisors Inc. raised its holdings in GSK by 4.7% in the first quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock valued at $261,000 after acquiring an additional 271 shares in the last quarter. Finally, First Affirmative Financial Network lifted its stake in GSK by 4.7% in the second quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock worth $245,000 after acquiring an additional 283 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Performance

GSK opened at $41.29 on Friday. GSK has a twelve month low of $33.67 and a twelve month high of $45.92. The firm has a market capitalization of $85.57 billion, a PE ratio of 14.96, a PEG ratio of 1.32 and a beta of 0.64. The company has a current ratio of 0.82, a quick ratio of 0.58 and a debt-to-equity ratio of 0.99. The firm’s 50-day moving average price is $39.73 and its 200 day moving average price is $41.46.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be issued a $0.3843 dividend. This represents a $1.54 annualized dividend and a yield of 3.72%. The ex-dividend date is Friday, August 16th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is 54.71%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.